



## Corporate Press Release

29 March 2012

### **NORGINE ENFORCES ITS TRADE MARK RIGHTS IN MOVI- PREFIX AND FORCES REBRANDING OF 2 LAXATIVES**

Norgine, the European specialty pharmaceutical company, has successfully taken legal action to ensure that Teva B.V. and Clonmel Healthcare Limited rebrand their laxative products so as not to use Norgine's MOVI- prefix.

Norgine's laxative MOVICOL is a treatment for chronic constipation and faecal impaction, and is the leading prescription laxative brand in Europe.

At the end of 2011, Teva B.V. launched a laxative in the Republic of Ireland under the name Movitev. Trade mark infringement proceedings were subsequently issued in the High Court in Dublin, and Norgine announced today that the case had been concluded following a settlement agreement. As part of the settlement, all Movitev products have now been recalled at distributor level and Teva B.V. undertook not to launch any gastroenterology product under a name consisting of or containing the word 'movi'.

Earlier this year, Clonmel Healthcare Limited obtained a marketing authorisation to launch a laxative in Ireland under the name Movilief. This product has not been launched yet, and Norgine is pleased to report that Clonmel has agreed to rebrand its product to a different name.

Commenting on this outcome, Peter Martin, COO, said that "Norgine will always take whatever steps are appropriate to protect its intellectual property. No person or organisation should ever think otherwise."

**ENDS**

#### **About Norgine**

Norgine is an independent, successful European specialty pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2011, Norgine's net product sales were €250 million and the company employs over 1,200 people.

Norgine's focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology and supportive care. The Company currently markets a range of products in various markets in its key therapeutic areas e.g. MOVICOL® for the treatment of constipation and faecal impaction, MOVIPREP® a bowel cleansing preparation, KLEAN-PREP® for large bowel preparation prior to colonoscopy or surgery, XIFAXAN® for the treatment of traveller's diarrhoea and ORAMORPH® for the treatment of moderate to severe pain associated with cancer.

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, UK and Dreux, France.

For more information: [www.norgine.com](http://www.norgine.com)

Norgine Contact:

Julie Hornby-Winfield

Global Corporate Communications Manager

Tel: +44 1895 826600 or email to [jhornbywinfield@norgine.com](mailto:jhornbywinfield@norgine.com)